Skin autofluorescence predicts cancer in subjects with type 2 diabetes

IntroductionSubjects with type 2 diabetes have an excess risk of cancer. The potential role of advanced glycation end products (AGEs) accumulated during long-term hyperglycemia in cancer development has been suggested by biological studies but clinical data are missing. AGEs can be estimated by meas...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:BMJ open diabetes research & care Ročník 9; číslo 1; s. e001312
Hlavní autori: Foussard, Ninon, Larroumet, Alice, Rigo, Marine, Mohammedi, Kamel, Baillet-Blanco, Laurence, Poupon, Pauline, Monlun, Marie, Lecocq, Maxime, Devouge, Anne-Claire, Ducos, Claire, Liebart, Marion, Battaglini, Quentin, Rigalleau, Vincent
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England American Diabetes Association 01.03.2021
BMJ Publishing Group LTD
BMJ Journals
BMJ Publishing Group
Predmet:
advanced glycation end product
Age
biomarkers
Body mass index
Cancer
Diabetes
Diabetic retinopathy
Endocrinology and metabolism
Gender
Glucose
Human health and pathology
Hyperglycemia
Kidney diseases
Life Sciences
Medical screening
Pathophysiology/Complications
Regression analysis
Santé publique et épidémiologie
Skin
Survival analysis
type 2 diabetes
Variables
advanced glycation end product
cancer
type 2 diabetes
biomarkers
Type 2 diabetes
Biomarkers
Cancer
Advanced glycation end product
ISSN:2052-4897, 2052-4897
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:IntroductionSubjects with type 2 diabetes have an excess risk of cancer. The potential role of advanced glycation end products (AGEs) accumulated during long-term hyperglycemia in cancer development has been suggested by biological studies but clinical data are missing. AGEs can be estimated by measuring the skin autofluorescence. We searched whether the skin autofluorescence could predict new cancers in persons with type 2 diabetes.Research design and methodsFrom 2009 to 2015, we measured the skin autofluorescence of 413 subjects hospitalized for uncontrolled or complicated type 2 diabetes, without any history of cancer. The participants were followed for at least 1 year and the occurrences of new cancers were compared according to their initial skin autofluorescences.ResultsThe participants were mainly men (57.9%), with poorly controlled (HbA1c 72±14 mmol/mol or 8.7%±1.8%) and/or complicated type 2 diabetes. Their median skin autofluorescence was 2.6 (2.2–3.0) arbitrary units. Forty-five new cancer cases (10.9%) were registered during 4.8±2.3 years of follow-up: 75.6% of these subjects had skin autofluorescence higher than the median (χ2: p=0.001). By Cox regression analysis adjusted for age, gender, body mass index, history of smoking and renal parameters, skin autofluorescence >2.6 predicted a 2.57-fold higher risk of cancer (95% CI 1.28 to 5.19, p=0.008). This association remained significant after excluding the eight cancers that occurred in the 4 years after inclusion (OR 2.95, 95% CI 1.36 to 6.38, p=0.006). As a continuous variable, skin autofluorescence was also related to new cancers (OR 1.05, 95% CI 1.01 to 1.10, p=0.045).ConclusionsSkin autofluorescence, a potential marker of glycemic memory, predicts the occurrence of cancer in subjects with type 2 diabetes. This relation provides a new clinical argument for the role of AGEs in cancer. Their estimation by measuring the skin autofluorescence may help select subjects with diabetes in cancer screening programs.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2052-4897
2052-4897
DOI:10.1136/bmjdrc-2020-001312